Vocalbeats.AI Achieves ISO/IEC 42001 Certification, Reinforcing Responsible AI Governance Celularity Announces Acceptance of Poster Presentation at 2023 Society for Biomaterials Annual Meeting
FLORHAM PARK, N.J., April 04, 2023 (GLOBE NEWSWIRE) — Celularity Inc. (Nasdaq: CELU) (“Celularity”), a…
Clearmind Medicine Announces Pricing of US$3.5 Million Public Offering
Tel Aviv, Israel / Vancouver, Canada, April 04, 2023 (GLOBE NEWSWIRE) — Clearmind Medicine Inc….
Clearmind Medicine Announces Pricing of US$3.5 Million Public Offering
Tel Aviv, Israel / Vancouver, Canada, April 04, 2023 (GLOBE NEWSWIRE) — Clearmind Medicine Inc….
AIM ImmunoTech Announces Central IRB Approval of Phase 2 Study Protocol Evaluating Ampligen® for the Treatment of Post-COVID Conditions
Preliminary data of Ampligen seen to date demonstrates potential to be an effective treatment option…
AIM ImmunoTech Announces Central IRB Approval of Phase 2 Study Protocol Evaluating Ampligen® for the Treatment of Post-COVID Conditions
Preliminary data of Ampligen seen to date demonstrates potential to be an effective treatment option…
Neuronetics Secures Up To $60 Million in New Debt Financing with SLR Capital Partners, Provides Greenbrook TMS with $6.0 Million Promissory Note
MALVERN, Pa., April 04, 2023 (GLOBE NEWSWIRE) — Neuronetics, Inc. (NASDAQ: STIM), a commercial stage…
Neuronetics Secures Up To $60 Million in New Debt Financing with SLR Capital Partners, Provides Greenbrook TMS with $6.0 Million Promissory Note
MALVERN, Pa., April 04, 2023 (GLOBE NEWSWIRE) — Neuronetics, Inc. (NASDAQ: STIM), a commercial stage…
LIXTE Biotechnology Announces Sarah Cannon Research Institute Joins City of Hope’s Ongoing Phase 1b Clinical Trial in Evaluating Lixte’s Lead Anti-Cancer Compound, LB-100, in Small Cell Lung Cancer
Clinical Trial Focuses on Assessing Whether LB-100 Enhances the Effectiveness of a Standard Regimen Combining…
LIXTE Biotechnology Announces Sarah Cannon Research Institute Joins City of Hope’s Ongoing Phase 1b Clinical Trial in Evaluating Lixte’s Lead Anti-Cancer Compound, LB-100, in Small Cell Lung Cancer
Clinical Trial Focuses on Assessing Whether LB-100 Enhances the Effectiveness of a Standard Regimen Combining…
OMNIMED™ Announces Integration of SmartOR™ Into Axis Research & Technologies Facilities
Roll-Out Across National Bioskills Training Centers Gives Med Device Companies and Surgeons Access to Intelligent…
OMNIMED™ Announces Integration of SmartOR™ Into Axis Research & Technologies Facilities
Roll-Out Across National Bioskills Training Centers Gives Med Device Companies and Surgeons Access to Intelligent…
Inozyme Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) to Newly Appointed Chief Operations Officer
BOSTON, April 04, 2023 (GLOBE NEWSWIRE) — Inozyme Pharma, Inc. (Nasdaq: INZY), a clinical-stage rare…
Inozyme Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) to Newly Appointed Chief Operations Officer
BOSTON, April 04, 2023 (GLOBE NEWSWIRE) — Inozyme Pharma, Inc. (Nasdaq: INZY), a clinical-stage rare…
Veru Announces Preclinical Results from Expanded Sabizabulin Program into Influenza-Induced Severe Acute Respiratory Distress Syndrome and Provides Update on COVID-19 Program
In the final report, sabizabulin significantly reduced key cytokines involved in Acute Respiratory Distress Syndrome…
Veru Announces Preclinical Results from Expanded Sabizabulin Program into Influenza-Induced Severe Acute Respiratory Distress Syndrome and Provides Update on COVID-19 Program
In the final report, sabizabulin significantly reduced key cytokines involved in Acute Respiratory Distress Syndrome…
SciSparc Receives Final Approval to Commence its Phase IIb Clinical Trial for SCI-110 to treat Tourette Syndrome
The Tel Aviv Sourasky Medical Center granted its final approval to use SCI-110 in a…
SciSparc Receives Final Approval to Commence its Phase IIb Clinical Trial for SCI-110 to treat Tourette Syndrome
The Tel Aviv Sourasky Medical Center granted its final approval to use SCI-110 in a…
Avid Bioservices Unveils Completed Mammalian Cell Facilities Expansion Providing Significantly Increased Capacity for Existing and Future Customers
Company to Host Open House to Celebrate Official Launch of Newest CGMP Mammalian Cell Manufacturing…
Avid Bioservices Unveils Completed Mammalian Cell Facilities Expansion Providing Significantly Increased Capacity for Existing and Future Customers
Company to Host Open House to Celebrate Official Launch of Newest CGMP Mammalian Cell Manufacturing…
Nexcella announces poster presentation at the European Society for Blood and Marrow Transplantation 49th Annual Meeting
Updated clinical data for NXC-201, a next-generation CAR-T for multiple myeloma and AL amyloidosis, will…